Immucor receives Nasdaq notice for delay in filing SEC reports

By Angela McDaniels

Seattle, Oct. 18 - Immucor, Inc. said Nasdaq has warned that its stock may be delisted because it is late filing its financial reports.

Because it has failed to file in a timely manner its form 10-Q for the period ended Aug. 31 and its form 10-K for the fiscal year ended May 31, the company has received a Nasdaq staff determination letter indicating it is not in compliance with Nasdaq Marketplace Rule 4310(c)(14). Immucor's common stock is now subject to delisting from the Nasdaq National Market.

Immucor has requested a hearing before a Nasdaq Listing Qualifications Panel, which automatically stayed the delisting pending a decision.

The company said the filing of its Form 10-K has been delayed in part by the need to complete an audit of its financial statements for the fiscal year ended May 31 and added that it continues to work diligently to finalize and file its form 10-K and form 10-Q as soon as possible.

The Norcross, Ga.-based biotechnology company manufactures and sells reagents and automated systems used to detect and identify certain properties of the cell and serum components of human blood prior to transfusion.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.